Preventing Seizures: Anticonvulsant Medications; Phenytoin (Dilantin SR), Valproic Acid (Depakine), and Levetiracetam (Keppra)

Comparison of the Drugs

Key Considerations for Prescribing Anticonvulsants

1. Individualized Treatment Approach: The choice of an anticonvulsant should be based on the seizure type, patient’s age, comorbid conditions, potential drug interactions, and patient preference.
2. Side Effect Management: Patients should be informed about possible side effects and monitored regularly to manage any adverse effects effectively.
3. Therapeutic Monitoring: Drugs like phenytoin and valproic acid require serum level monitoring to optimize therapeutic outcomes and avoid toxicity.
4. Special Populations: Dose adjustments may be necessary for elderly patients, those with renal or hepatic impairment, and during pregnancy (as some anticonvulsants are teratogenic).
5. Drug Interactions: Some anticonvulsants can interact with other medications, affecting their metabolism and efficacy. This is particularly important when using phenytoin and valproic acid, which are metabolized by the liver.

---

Introduction

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. Anticonvulsant medications, also known as antiepileptic drugs (AEDs), are the cornerstone of epilepsy management, aiming to reduce the frequency and severity of seizures, and in some cases, to achieve complete seizure control. This article provides a detailed review of three commonly used anticonvulsants for preventing seizures: Phenytoin (Dilantin SR), Valproic Acid (Depakine), and Levetiracetam (Keppra). Each drug's mechanism of action, indications, dosages, and potential side effects will be discussed.

1. Phenytoin (Dilantin SR)

Mechanism of Action

Phenytoin works by stabilizing the neuronal membrane and decreasing excitability. It achieves this by blocking voltage-gated sodium channels, reducing the propagation of abnormal electrical discharges in the brain that can lead to seizures. This action helps to raise the seizure threshold, making it less likely for a seizure to occur.

Indications

Phenytoin is widely used to treat generalized tonic-clonic (grand mal) seizures and focal (partial) seizures. It is not typically recommended for absence or myoclonic seizures, as it may worsen these conditions.

Dosage and Administration

• Standard Dose: The usual starting dose for adults is 100 mg three times daily (TID), which can be adjusted based on the patient's response and serum drug levels. The goal is to maintain therapeutic blood levels between 10-20 mcg/mL.
• Sustained-Release Form (SR): This formulation allows for more consistent blood levels, reducing the frequency of dose adjustments and minimizing fluctuations in drug concentration.

Side Effects

Common side effects include dizziness, drowsiness, and coordination problems. Long-term use can lead to:

• Gingival hyperplasia: Overgrowth of gum tissue, which can be minimized with good oral hygiene.
• Osteoporosis: Chronic phenytoin use may reduce bone density, so regular bone health assessments and supplements (calcium and vitamin D) may be necessary.
• Other Risks: Hepatotoxicity, megaloblastic anemia (due to folate deficiency), and peripheral neuropathy.

Monitoring

Regular monitoring of serum phenytoin levels is essential to ensure therapeutic efficacy and to avoid toxicity. Liver function tests should also be performed periodically due to the risk of hepatic side effects.

2. Valproic Acid (Depakine)

Mechanism of Action

Valproic acid enhances the inhibitory effects of gamma-aminobutyric acid (GABA) in the brain, a neurotransmitter that calms neuronal activity. It also blocks voltage-gated sodium channels and modulates calcium channel activity, making it a broad-spectrum antiepileptic.

Indications

Valproic acid is effective for various seizure types, including generalized seizures (tonic-clonic, myoclonic, and absence) and focal seizures. It is also used in the treatment of bipolar disorder and for migraine prophylaxis.

Dosage and Administration

• Standard Dose: For adults, the starting dose is typically 500 mg twice daily, which can be increased as needed. The therapeutic serum level ranges between 50-100 mcg/mL.
• Formulations: Available as tablets, capsules, and liquid forms, facilitating tailored dosing for individual patients.

Side effects

while generally well-tolerated, potential side effects include:

• Weight Gain: This is a common issue and may be dose-related.
• Hair Loss: Some patients experience thinning or loss of hair.
• Tremors: Mild tremors can occur, especially at higher doses.
• Hepatotoxicity: Regular liver function monitoring is required, particularly in the first six months of therapy.
• Thrombocytopenia: It can cause a reduction in platelet count, necessitating periodic complete blood count (CBC) monitoring.

Monitoring

routine liver function tests and CBC should be conducted, especially during the initial phase of treatment. Additionally, valproic acid levels should be checked periodically to ensure they remain within the therapeutic range.

3. Levetiracetam (Keppra)

Mechanism of Action

Levetiracetam's precise mechanism is not entirely understood but is thought to involve modulation of synaptic vesicle protein 2A (SV2A), which influences neurotransmitter release. This action helps to stabilize neuronal activity and reduce the likelihood of seizure episodes.

Indications

Levetiracetam is used as an adjunctive treatment for various seizure types, including focal seizures, generalized tonic-clonic seizures, and myoclonic seizures in juvenile myoclonic epilepsy.

Dosage and Administration

• Standard Dose: The typical adult dose starts at 500 mg twice daily, which can be titrated up to 1500 mg twice daily based on the patient's response and tolerance.
• Advantages: It is available in multiple forms, including oral tablets, liquid solution, and intravenous (IV) formulations, allowing flexibility in dosing.

Side Effects

Levetiracetam is generally well-tolerated, with a favorable side effect profile. Possible adverse effects include:

• Mood Changes: Can cause irritability, aggression, or depression in some patients.
• Fatigue and Drowsiness: May occur, especially during initial treatment or dose increases.
• Dizziness and Coordination Problems: Occasionally reported but tend to be mild and transient.

Monitoring

Unlike phenytoin and valproic acid, routine blood level monitoring is not typically required for levetiracetam. However, patients should be regularly assessed for mood changes and any signs of behavioral side effects.

---

Conclusion

Anticonvulsants such as Phenytoin, Valproic Acid, and Levetiracetam play a critical role in preventing seizures in patients with epilepsy. Understanding each drug’s mechanism of action, appropriate indications, dosing, and monitoring requirements helps in optimizing seizure management and improving patient outcomes. Regular follow-up and patient education are crucial to ensure adherence to treatment and early detection of potential side effects.

By tailoring the choice of anticonvulsants to individual patient needs, clinicians can effectively control seizures while minimizing adverse effects, thus enhancing the quality of life for patients living with epilepsy.